Navigation Links
Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome
Date:1/15/2014

ences.  Key hormones, including adiponectin and leptin, also showed changes characteristic of non-PWS obese patients, demonstrating that the drug was highly active in these patients and had a similar effect to that seen in non-PWS patients.

"These results are very exciting for the treatment of PWS, as most patients showed improvements in body weight, hunger-related behaviors, and body fat content, despite the increased food intake included in the trial design," explained Dr. Jennifer Miller, Associate Professor of Pediatric Endocrinology, University of Florida, and Principal Investigator for the study.  "PWS is a complex genetic disease that is difficult to treat and the results of this trial demonstrate that beloranib has a beneficial impact on this underserved patient population.  Notably, we were encouraged by reports of fullness, a first-time occurrence for PWS patients who otherwise lack the capacity to feel sated after meals."

"PWS patients remain severely impacted by their disease and are not treatable with other anti-obesity agents," added Janalee Heinemann, Director of Research & Medical Affairs for the Prader-Willi Syndrome Association (USA).  "PWS represents one of the most severe forms of genetic obesity and we welcome these results, which are a significant step towards finding a treatment for those suffering from this life threatening condition."

Beloranib, a novel obesity therapy that utilizes a unique mechanism of action, is being studied for its ability to reduce body weight and improve cardiometabolic risk factors in obese patients with and without PWS.  This study was a randomized, double-blind, placebo-controlled trial to evaluate the safety and tolerability of a dose range of beloranib administered as twice-weekly subcutaneous injections for four weeks.  The randomized treatment part of the study was follow
'/>"/>

SOURCE Zafgen, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Zafgen Announces Initiation of Phase 2a Clinical Development with Beloranib in Obesity
2. Zafgen Secures $21 Million in Series D Financing
3. Zafgen Announces New Weight Loss and Safety Data from Phase 2 Study of Beloranib in Obesity at Obesity Week 2013
4. Zafgen Secures $45 Million in Series E Financing
5. Zafgen Appoints Chief Commercial Officer and New Member of Board of Directors
6. Precision Optics Corporation Announces $1 Million Order for Microprecision™ Based Endoscopes
7. Young Innovations, Inc. Announces Record Sales and EPS for the Quarter Ended March 31, 2012
8. JDRF Announces Research Collaboration with Dexcom, Inc. to Develop "Smart Transmitter" Technology to Accelerate Artificial Pancreas Studies
9. Misonix Announces New Distribution Agreement For Panama
10. University of Maryland BioPark Announces MedImmunes Dr. Bahija Jallal as Newest Member of Board of Directors for UM Health Sciences Research Park
11. Novelos Therapeutics Announces Successful Completion of First Cohort In Lung Cancer Trial With I-124-CLR1404 (LIGHT) Cancer-Targeted PET Imaging Agent at UW Carbone Cancer Center
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/2/2015)... March 2, 2015  Tandem Diabetes Care®, Inc. (NASDAQ: ... manufacturer of the t:slim® and t:flex™ Insulin Pumps, today ... offering of common stock have exercised their option to ... at a price to the public of $11.50 per ... is expected to be $64.8 million, after deducting underwriting ...
(Date:3/2/2015)... , March 2, 2015 Valencia Technologies ... th patient with its radically small device for ... 2015. Valencia,s early results in this randomized, double-blinded, controlled trial ... degree of confidence that it will succeed in a ... its early clinical results, Valencia ...
(Date:3/2/2015)... NEW YORK , March 2, 2015 For the ... million car accidents per year in the U.S. alone (U.S. Census ... goodness most are minor fender benders BUT there are quite a ... due to cabin intrusion, which can obstruct the seatbelt release button ... to avoid being in any serious accidents in their lifetime but ...
Breaking Medicine Technology:Tandem Diabetes Care Announces Exercise of Option to Purchase Additional Shares in Underwritten Public Offering of Common Stock 2Tandem Diabetes Care Announces Exercise of Option to Purchase Additional Shares in Underwritten Public Offering of Common Stock 3Valencia Technologies Implants its 48th Patient, Continues Equity Crowdfunding 2New SuperVizor, an Automobile Escape Tool, Ensures the Safety of Drivers and Passengers on the Road 2
... UCB, Inc. today announced an agreement with ... disclosed government investigation into the marketing and promotion of Keppra®, ... were the subject of this investigation occurred more than six ... cooperated fully with the United States since learning of the ...
... A post hoc analysis from the RECOVER study ... Transdermal System) suggested that patients with Parkinson,s disease who ... key markers of mood/cognition, such as taking interest in ... Additional data presented from a one year open ...
Cached Medicine Technology:UCB, Inc. Resolves Investigation of Past Keppra® Marketing and Promotional Activities 2Post Hoc Analysis from RECOVER Study Examined Effects of Neupro® (Rotigotine Transdermal System) on Surrogate Markers of Mood and Anhedonia in Parkinson's Disease 2Post Hoc Analysis from RECOVER Study Examined Effects of Neupro® (Rotigotine Transdermal System) on Surrogate Markers of Mood and Anhedonia in Parkinson's Disease 3Post Hoc Analysis from RECOVER Study Examined Effects of Neupro® (Rotigotine Transdermal System) on Surrogate Markers of Mood and Anhedonia in Parkinson's Disease 4Post Hoc Analysis from RECOVER Study Examined Effects of Neupro® (Rotigotine Transdermal System) on Surrogate Markers of Mood and Anhedonia in Parkinson's Disease 5Post Hoc Analysis from RECOVER Study Examined Effects of Neupro® (Rotigotine Transdermal System) on Surrogate Markers of Mood and Anhedonia in Parkinson's Disease 6
(Date:3/2/2015)... 2015 Cutler Integrative Medicine a leader ... root, gives cutting-edge tips to bring about self-renewal. A ... the body by first cleaning house. According to ... are all Toxic.” Between environmental toxins like heavy metals, ... and our high stress levels, we all have a ...
(Date:3/2/2015)... Surgeons at the Forbes Hospital ... are exploring an innovative use of Google Glass ... Reminder (VIZR), to assist in the care of critically ... a wearable technology with an optical head-mounted display that ... with the Internet via natural language voice commands. , ...
(Date:3/2/2015)... NY (PRWEB) March 02, 2015 ... history of catalyzing private sector activities and investments ... has recently elected four new members to serve ... welcomes Dr. Paul Farmer, Chief Strategist and Co-founder ... at Harvard University; Dr. Huma Abbasi, General Manager ...
(Date:3/2/2015)... March 02, 2015 Market Publishers Ltd ... worked out by Global Industry Analysts Inc and recently ... Market Research Report . Through 2018, the global radiation ... CAGR. The detailed research report suggests a holistic analysis ... therapy equipment as well as covers the top market ...
(Date:3/2/2015)... New York, NY (PRWEB) March 02, 2015 ... & Drug Administration (FDA) warned against the use ... invasive hysterectomies and fibroid removal surgeries, insurer UnitedHealthCare ... require the use of those devices. In a ... said that beginning in April, it would require ...
Breaking Medicine News(10 mins):Health News:Skin and Wellness Power Couple give Quick Tips to Self-Renewal for Spring 2Health News:Pennsylvania Hospital Explores Use of Google Glass for Trauma Care 2Health News:Pennsylvania Hospital Explores Use of Google Glass for Trauma Care 3Health News:Dr. Paul Farmer and Leaders from Chevron, Johnson & Johnson and Merck Join GBCHealth’s Board of Directors 2Health News:Dr. Paul Farmer and Leaders from Chevron, Johnson & Johnson and Merck Join GBCHealth’s Board of Directors 3Health News:Dr. Paul Farmer and Leaders from Chevron, Johnson & Johnson and Merck Join GBCHealth’s Board of Directors 4Health News:Dr. Paul Farmer and Leaders from Chevron, Johnson & Johnson and Merck Join GBCHealth’s Board of Directors 5Health News:New Topical Research Reports Prepared by GIA Now Available at MarketPublishers.com 2Health News:New Topical Research Reports Prepared by GIA Now Available at MarketPublishers.com 3Health News:Power Morcellator Lawyers at Bernstein Liebhard LLP Comment on Insurers’ Decision to Restrict Most Common Form of Hysterectomies 2Health News:Power Morcellator Lawyers at Bernstein Liebhard LLP Comment on Insurers’ Decision to Restrict Most Common Form of Hysterectomies 3Health News:Power Morcellator Lawyers at Bernstein Liebhard LLP Comment on Insurers’ Decision to Restrict Most Common Form of Hysterectomies 4
... of the 20th anniversary of the record-setting Magnum XL-200 roller ... teaming up with Cedar Point amusement park/resort to hold an ... riders of Magnum,s historic 2009 season.The Red Cross is auctioning ... starting at $75. All riders must be 48 inches ...
... Study in mice finds added benefit from cholesterol-reducing ... -- Drugs that stimulate cells to release cholesterol ... which causes AIDS, a new study suggests. , ... TO-901317 in mice and found that the treatment ...
... link between body fat and cancer identified by a ... could lead to new cancer treatment and prevention strategies. ... nutrition researcher with the Michigan Agricultural Experiment Station, identified ... killer of Americans, in part by examining tissue hormones. ...
... group of arthritidies that share clinical features ... at sites where tendons attach to bone. ... inflammatory bowel-disease-related arthritis, reactive arthritis (ReA) and ... Chlamydia pneumoniae (which are often asymptomatic) frequently ...
... and Other Healthcare ProfessionalsDALLAS, April 30 ... outbreak, T-System, Inc., the nation,s largest provider of ... the release of free downloadable charting templates with ... and Prevention (CDC) guidelines for testing and treatment ...
... a leading manufacturer of cold chain management solutions ... all products that help ensure product efficacy for ... to monitor and record temperature, and can be ... pharmaceuticals.Many vaccines and pharmaceuticals have temperature sensitivity where ...
Cached Medicine News:Health News:Firelands Chapter of the American Red Cross to Auction First Rides on Magnum's 20th Anniversary 2Health News:Cancer-obesity link discovery by MSU researchers could aid prevention efforts 2Health News:Chlamydia may play role in a type of arthritis 2Health News:T-System Releases Free Clinician Swine Flu Templates, Incorporating Updated CDC Interim Guidelines for Diagnosis and Treatment 2Health News:DeltaTRAK Responds to Swine Flu Outbreak With Full Line of Products for Temperature Sensitive Vaccines 2
Each handle is designed to fit a specific trephine size. For use in performing free-hand uniform donor buttons....
Each handle is designed to fit a specific trephine size. For use in performing free-hand uniform donor buttons....
Each handle is designed to fit a specific trephine size. For use in performing free-hand uniform donor buttons....
Each handle is designed to fit a specific trephine size. For use in performing free-hand uniform donor buttons....
Medicine Products: